New York, January 26, 2026, 14:55 EST — Regular session
- Boston Scientific shares climbed roughly 2% in afternoon trading, outpacing the broader market
- Evercore sticks with Outperform and a $112 price target, calling concerns over demand and the Penumbra deal “overdone”
- Attention shifts to the Feb. 4 results for updated guidance and fresh details on integration and financing
Shares of Boston Scientific Corp climbed 1.7% to $94.12 Monday afternoon, gaining $1.61 since Friday’s close. The stock fluctuated between $92.03 and $94.24, with roughly 5.4 million shares traded by mid-afternoon.
Boston Scientific is gearing up to release its fourth-quarter and full-year 2025 results on Feb. 4. Investors will be watching closely for updates on procedure demand and pricing trends. CEO Mike Mahoney and CFO Jon Monson are scheduled to hold a conference call at 8 a.m. ET that day. 1
The deal lands amid ongoing debate over Boston Scientific’s $14.5 billion cash-and-stock acquisition of Penumbra, set to finalize in 2026. Penumbra CEO Adam Elsesser will join Boston’s board once the transaction closes. On the analyst call, Mahoney described the deal as a “home run” and “financially compelling.” Truist analyst Richard Newitter added it fills a key gap in Boston Scientific’s neurovascular lineup. 2
Boston Scientific led the pack among major medical-device stocks. Abbott ticked up around 0.8%, Medtronic climbed about 0.5%, and Stryker gained roughly 0.7%. The SPDR S&P 500 ETF rose close to 0.7% as well.
Evercore ISI stuck with its Outperform rating on Boston Scientific, signaling the stock should outpace its rivals, and held firm on a $112 price target. The firm added the stock to its “Tactical Outperform” list ahead of upcoming earnings. It dismissed concerns about procedure slowdowns and doubts surrounding the Penumbra acquisition as “overdone.” Evercore highlighted Farapulse’s market share gains in Japan following its early-2025 rollout. Boston Scientific currently trades at around 26 times earnings, which the firm sees as reasonable given its forecast of about 10% organic growth—excluding currency effects and acquisitions—and a “teens” earnings-per-share growth profile. 3
Boston Scientific plans to cover the roughly $11 billion cash portion of its Penumbra acquisition using a combination of cash reserves and new debt. The company projects the deal will reduce adjusted earnings per share by 6 to 8 cents in the first full year post-close, before moving to neutral or slightly accretive in year two. 4
That near-term dilution is crucial since Monday’s bounce doesn’t address the bigger issue: how much debt the company will rack up, nor the impact on margins as it brings a large batch of new products and sales teams on board.
Investors are looking for new insights on electrophysiology as Boston Scientific ramps up Farapulse to challenge established players and recent market entrants. Even minor shifts in market share or hospital uptake could rapidly impact growth rates in this area.
The rally might lose steam if procedure volumes dip or if regulators intensify scrutiny of the Penumbra deal, potentially delaying the closing timeline. On top of that, a tougher interest-rate environment would push up debt costs and squeeze first-year earnings.
Boston Scientific’s next key event arrives on Feb. 4, with earnings due before the bell and a conference call set for 8 a.m. ET to field questions.
